Thoracic Key

Author (ref) Year No. of patients Operative mortality % Survival rates, 5 years (%) Overall NO N1 N2 Piehler [8] 1982 66 15.2 32.9 54.0 7.4a 7.4a Patterson [9] 1982…

Fig. 15.1 Zoledronic acid reduced percentage of patients with each SRE. Phase III trial of patients with bone metastases from NSCLC/OST who received ZOL or placebo every 3 weeks for…

and Martin Reck1 (1) Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Woehrendamm 80, 22927 Grosshansdorf, Germany   Introduction Non-small…

Fig. 8.1 Homologous recombination and nonhomologous end joining process Furthermore, inhibition of RNF8 activity can suppress BRCA1, independent of HR in tumor cells with low 53BP1, and RNF8 could establish…

Fig. 11.1 RAS protein GTPase activation and inactivation [7] Mutation in the RAS proto-oncogene, one of the most common mutations in NSCLC, is found in 15–30 % NSCLC. Most RAS…

Study N Population Study question Comparison Findings Fischer 189 Resectable stage I-III NSCLC Number of ‘futile thoracotomies’ CS - > S 52 % vs. 35 % (P = 0.05) PET-CT - > S Maziak 337 Resectable…

Fig. 6.1 IMRT plan showing dose distribution in a locally advanced unresectable apical NSCLC Although no prospective randomized study comparing 3D conformal radiation therapy (3DCRT) to IMRT in lung cancer…

Fig. 5.1 The ITACA (International Tailored Chemotherapy Adjuvant Trial), a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stages II–IIIA NSCLC From…